CENTRAL NERVOUS SYSTEM
At Avanzia Pharma, we are aware of the growing recognition of the fundamental role of mental health in achieving global development goals, as reflected in the inclusion of mental health in the Sustainable Development Goals.
We are deeply concerned about the prevalence of mental disorders and their impacts on society.
Depression, which constitutes one of the leading causes of disability, and suicide, as the second leading cause of death among people aged 15 to 29, are significant issues.
Furthermore, it is concerning that individuals with severe mental disorders have a significantly reduced life expectancy, dying prematurely up to two decades earlier due to preventable physical illnesses.
- One in every eight people in the world suffers from a mental disorder.
- Mental disorders involve significant disruptions in thinking, emotion regulation, or behavior.
- There are many different types of mental disorders.
- Effective prevention and treatment options exist.
- Most people lack access to effective care.
AVANZIA PHARMA
DATA AND FIGURES FROM OMS
In recent years, the important role of mental health in achieving global development goals has been increasingly recognized, as illustrated by the inclusion of mental health in the Sustainable Development Goals.
Depression is one of the leading causes of disability. Suicide is the second leading cause of death among people aged 15 to 29. People with severe mental health disorders die prematurely (up to two decades earlier) due to preventable physical illnesses.
AVANZIA PHARMA
CENTRAL NERVOUS SYSTEM
At Avanzia Pharma, we are committed to promoting effective prevention and treatment options for mental disorders.
We recognize the importance of ensuring adequate and equitable access to mental health care, as most people lack access to effective care.
Through our work as a marketer of innovative pharmaceutical products, we strive to collaborate with companies and develop therapeutic solutions that address the challenges of mental health.
We work to provide high-quality and trusted medications that contribute to the well-being and improve the quality of life of people with mental disorders.
At Avanzia Pharma, we are committed to being part of positive change and promoting mental health as a global priority.
Our goal is to contribute to the reduction of the burden of mental disorders, ensuring access to effective treatment options, and supporting initiatives that promote awareness and inclusion in this highly relevant field.
SUCCESS STORIES
- General: Support in opening subsidiaries for an international group specializing in CNS
- Epilepsy: Omnichannel promotion of leading antiepileptic drug families since 2014, involving doctors, patients, and high-return outletstos de venta con elevados retornos de la inversión
- Parkinson’s: Promotion and support for an established brand to patients
- Migraine and Vertigo: Virtual visits to general practitioners and specialists, expanding coverage to previously uncovered areas.
- Pain: Launch and promotion of innovative products for mild to moderate, severe, and neuropathic pain from leading pain management specialist companies Launch of chronic severe pain treatment in adults requiring intrathecal analgesia (ITA).
- Depression: Successful launch of a new molecule with a novel mechanism of action Promotion in 11 Latin American countries of a leading range of antidepressants.
- TDAH: Omnichannel promotion to pharmacies and doctors in Spain Promotion of first-choice treatment in 6 Latin American countries.
BE PART OF OUR TEAM
WORK WITH US
We are an innovative laboratory that adds value to patients through the marketing of high-quality and trusted medications.
If you are passionate about this field and are looking to be part of a team committed to excellence, we invite you to join us.
AVANZIA PHARMA
CONTACT US